ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,970.84
0.00%
Dow Jones
42,992.21
0.00%
US Dollar vs MXN
20.3876
0.31%
Brent Oil
74.185
0.76%
Bitcoin
92,662.98
-0.92%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX
  6. IGC Pharma Inc (IGC)

  7. IGC Pharma Inc (IGC) Noticias

IGC

IGC Pharma (IGC)

IGC Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:AMEX:IGC
FechaHoraFuenteTítuloSímboloCompañía
25/11/202407:30Business WireIGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's TreatmentAMEX:IGCIGC Pharma Inc
12/11/202415:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:IGCIGC Pharma Inc
27/09/202415:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:IGCIGC Pharma Inc
27/09/202415:05Edgar (US Regulatory)Form 8-K - Current reportAMEX:IGCIGC Pharma Inc
18/09/202407:00Business WireIGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's TreatmentAMEX:IGCIGC Pharma Inc
04/09/202407:00Business WireIGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's DiseaseAMEX:IGCIGC Pharma Inc
26/08/202418:00Business WireIGC Announces Results of its 2024 Annual Stockholders MeetingAMEX:IGCIGC Pharma Inc
22/08/202408:00Business WireIGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's DiseaseAMEX:IGCIGC Pharma Inc
20/08/202407:00Business WireIGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 AgonistAMEX:IGCIGC Pharma Inc
14/08/202415:23Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]AMEX:IGCIGC Pharma Inc
08/08/202420:30Business WireIGC Pharma Reports First Quarter Fiscal 2025 ResultsAMEX:IGCIGC Pharma Inc
18/07/202408:00Business WireIGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price TargetAMEX:IGCIGC Pharma Inc
09/07/202413:17Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialAMEX:IGCIGC Pharma Inc
09/07/202408:10Business WirePreclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety ProfileAMEX:IGCIGC Pharma Inc
08/07/202415:07Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:IGCIGC Pharma Inc
25/06/202408:00Business WireIGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's DiseaseAMEX:IGCIGC Pharma Inc
24/06/202418:30Business WireIGC Reports Financial Results for Fiscal Year Ended March 31, 2024AMEX:IGCIGC Pharma Inc
18/06/202408:00Business WireIGC Pharma to Participate in Fireside Chat with Ascendiant Capital MarketsAMEX:IGCIGC Pharma Inc
10/06/202408:00Business WireIGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 TetrahydrocannabinolAMEX:IGCIGC Pharma Inc
28/05/202408:00Business WireIGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1AMEX:IGCIGC Pharma Inc
21/05/202420:20Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipAMEX:IGCIGC Pharma Inc
21/05/202413:00Business WireIGC Pharma to Attend BIO International Convention 2024AMEX:IGCIGC Pharma Inc
13/05/202420:53Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:IGCIGC Pharma Inc
16/04/202406:00Business WireIGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week TwoAMEX:IGCIGC Pharma Inc
09/04/202408:00Business WireIGC Pharma Adds Advisor in Artificial IntelligenceAMEX:IGCIGC Pharma Inc
26/03/202414:00Business WireIGC Pharma Announces $3 Million Unregistered Private Placement of its Common StockAMEX:IGCIGC Pharma Inc
20/03/202410:00Business WireIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s AgitationAMEX:IGCIGC Pharma Inc
20/03/202406:00Business WireIGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024AMEX:IGCIGC Pharma Inc
12/03/202414:00Business WireIGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s PipelineAMEX:IGCIGC Pharma Inc
28/02/202412:00Business WirePromising Results: TGR-63 Enhances Memory in Alzheimer's Mouse ModelAMEX:IGCIGC Pharma Inc
 Showing the most relevant articles for your search:AMEX:IGC

Su Consulta Reciente

BIT
YIV
Societe Generale Accepta...
LSE
72XF
07jun2034c
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados